$95 Million Says Cardiovascular Drugs Were Marketed Improperly
$95 Million Says Cardiovascular Drugs Were Marketed Improperly The U.S. Justice Department had a lot to say about the way Boehringer Ingelheim Pharmaceuticals Inc. was promoting four of their prescription medications. A $95 million settlement resolves the allegations at Boehringer Ingelheim’s promotion of Aggrenox, Combivent, and Micardis, as well as dosage issues with Atrovent. The […]
